This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (7)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in this journal  Topic Collections  • Lipids and Lipid Disorders  • Alert me on articles by topic

Current Perspectives

Arch Intern Med. 1999;159:1038-1040.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

THE DIRECT RELATION between elevations in low-density lipoprotein cholesterol (LDL-C) and increased risk of coronary heart disease (CHD) is widely accepted in the clinical setting. Furthermore, a number of controlled clinical trials have confirmed that pharmacologic management of LDL-C can markedly reduce the incidence of acute coronary events in selected patients both with and without clinically known CHD.^1-4

Less clear is the significance of clinical intervention in patients with low concentrations of high-density lipoprotein cholesterol (HDL-C). High-density lipoprotein cholesterol has been repeatedly shown to be an independent inverse predictor of CHD risk in epidemiological and observational studies, and patients with low HDL-C levels have been suggested to have a comparable CHD risk as those with high LDL-C levels.^5-6 In this issue of the ARCHIVES, Harper and Jacobson⁷ provide a comprehensive review of the current status of isolated low HDL-C (ILHDL-C) as a risk factor for CHD.⁷

THE ROLE OF HDL IN ATHEROGENESIS

The family of HDL . . . [Full Text of this Article]

PROGNOSTIC SIGNIFICANCE OF LOW HDL-C

HDL-C AS A SYNERGISTIC CHD RISK FACTOR

CLINICAL BENEFIT OF TREATING PATIENTS WITH LOW HDL-C

LOW HDL-C: GUIDING TREATMENT DECISIONS

CONCLUSIONS

RELATED ARTICLE

New Perspectives on the Management of Low Levels of High-Density Lipoprotein Cholesterol
Charles R. Harper and Terry A. Jacobson
Arch Intern Med. 1999;159(10):1049-1057.
ABSTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Use of Simvastatin Treatment in Patients With Combined Hyperlipidemia in Clinical Practice
Vicari et al.
Arch Fam Med 2000;9:898-905.
ABSTRACT | FULL TEXT  

Gemfibrozil, nicotinic acid and combination therapy in patients with isolated hypoalphalipoproteinemia: a randomized, open-label, crossover study
Zema
J Am Coll Cardiol 2000;35:640-646.
ABSTRACT | FULL TEXT  

Carbohydrate-induced hypertriacylglycerolemia: historical perspective and review of biological mechanisms1
Parks and Hellerstein
Am. J. Clin. Nutr. 2000;71:412-433.
ABSTRACT | FULL TEXT